Literature DB >> 4374836

Infectious mononucleosis at the United States Military Academy. A prospective study of a single class over four years.

T J Hallee, A S Evans, J C Niederman, C M Brooks, j H Voegtly.   

Abstract

A prospective study of EB virus infections was initiated in July, 1969 in the entering class of 1401 cadets, at the U.S. Military Academy at West Point, N.Y. and continued over 4 yr. On entry 63.5% possessed EBV antibody and 36.5 lacked EBV antibody. The rate of antibody prevalence varied with the geographic area from which the cadet originated.Except in two cadets already ill on first bleeding no evidence of clinical infectious mononucleosis (I.M.) occurred over the 4 yr period in the 890 cadets entering the Academy with EBV antibody. Among 437 cadets without antibody on entry, 54 or 12.4% were infected (seroconverted) in the freshman year; 15 of these had clinical I.M., 12 had suggestive I.M., and 39 had no known mono-like illness. The annual infection rates in susceptible cadets in the second, third, and fourth years were 24.4, 15.1, and 30.8 per 100, respectively. Of 201 cadets infected with EBV over 4 yr only 26.4% were manifested by heterophile positive clinical infectious mononucleosis. Overall, 46% of the 437 cadets entering without EBV antibody became infected over 40 mo of serologic observation; definite clinical infectious mononucleosis developed in 53 cadets, a clinical attack rate of 12.1 per 100 for 4 yr. The EBV infection rate among exposed and susceptible roommates of known cases was no higher than in roommates not so exposed.Elevations of EBV-specific and total IgM occurred during acute illness and disappeared in late convalescence. Total IgG and IgA levels were less commonly elevated. EBV-specific-IgM antibody was demonstrable during the acute illness but was absent 12 mo later. Analysis of EBV infection rates revealed no difference among persons of different ABO blood groups.

Entities:  

Mesh:

Substances:

Year:  1974        PMID: 4374836      PMCID: PMC2595096     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  16 in total

1.  The transmission of infectious mononucleosis.

Authors:  R J HOAGLAND
Journal:  Am J Med Sci       Date:  1955-03       Impact factor: 2.378

2.  Infectious mononucleosis in University of Wisconsin students. Report of a five-year investigation.

Authors:  A S EVANS
Journal:  Am J Hyg       Date:  1960-05

3.  Infectious mononucleosis and other mono-like syndromes.

Authors:  A S Evans
Journal:  N Engl J Med       Date:  1972-04-13       Impact factor: 91.245

4.  Serological studies on cytomegalovirus infection in relation to infectious mononucleosis and similar conditions.

Authors:  B Wahren; A Espmark; G Walldén
Journal:  Scand J Infect Dis       Date:  1969

5.  Prospective studies of a group of Yale University freshmen. II. Occurrence of acute respiratory infections and rubella.

Authors:  A S Evans; J C Niederman; R N Sawyer
Journal:  J Infect Dis       Date:  1971-03       Impact factor: 5.226

6.  Prospective studies of a group of Yale University freshmen. I. Occurrence of infectious mononucleosis.

Authors:  R N Sawyer; A S Evans; J C Niederman; R W McCollum
Journal:  J Infect Dis       Date:  1971-03       Impact factor: 5.226

7.  Prevalence, incidence and persistence of EB virus antibody in young adults.

Authors:  J C Niederman; A S Evans; L Subrahmanyan; R W McCollum
Journal:  N Engl J Med       Date:  1970-02-12       Impact factor: 91.245

8.  Immunofluorescence in cells derived from Burkitt's lymphoma.

Authors:  G Henle; W Henle
Journal:  J Bacteriol       Date:  1966-03       Impact factor: 3.490

9.  Seroepidemiologic studies of infectious mononucleosis with EB virus.

Authors:  A S Evans; J C Niederman; R W McCollum
Journal:  N Engl J Med       Date:  1968-11-21       Impact factor: 91.245

10.  Infectious mononucleosis. Clinical manifestations in relation to EB virus antibodies.

Authors:  J C Niederman; R W McCollum; G Henle; W Henle
Journal:  JAMA       Date:  1968-01-15       Impact factor: 56.272

View more
  29 in total

Review 1.  Recovery from infectious mononucleosis: a case for more than symptomatic therapy? A systematic review.

Authors:  Bridget Candy; Trudie Chalder; Anthony J Cleare; Simon Wessely; Peter D White; Matthew Hotopf
Journal:  Br J Gen Pract       Date:  2002-10       Impact factor: 5.386

2.  EB virus antibody and infectious mononucleosis in a boarding school for boys.

Authors:  T W Hoskins; W B Fletcher; J M Blake; M S Pereira; J M Edwards
Journal:  J Clin Pathol       Date:  1976-01       Impact factor: 3.411

3.  Infectious mononucleosis and mononucleosis syndromes.

Authors:  M Fiala; D C Heiner; J A Turner; B Rosenbloom; L B Guze
Journal:  West J Med       Date:  1977-06

4.  Laboratory diagnosis of EB virus infection in some cases presenting as hepatitis.

Authors:  J M Edwards; E M Vandervelde; B J Cohen; D A McSwiggan
Journal:  J Clin Pathol       Date:  1978-02       Impact factor: 3.411

5.  Incidence of Infectious Mononucleosis in Universities and U.S. Military Settings.

Authors:  Yolonda J Williams-Harmon; Leonard A Jason; Ben Z Katz
Journal:  J Diagn Tech Biomed Anal       Date:  2014-11-21

Review 6.  Progress and problems in understanding and managing primary Epstein-Barr virus infections.

Authors:  Oludare A Odumade; Kristin A Hogquist; Henry H Balfour
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 7.  Clinical consequences of Epstein-Barr virus infection and possible control by an anti-viral vaccine.

Authors:  M A Epstein; A J Morgan
Journal:  Clin Exp Immunol       Date:  1983-08       Impact factor: 4.330

8.  Limitations of available tests for diagnosis of infectious mononucleosis.

Authors:  G R Fleisher; M Collins; S Fager
Journal:  J Clin Microbiol       Date:  1983-04       Impact factor: 5.948

9.  Myths about infectious mononucleosis.

Authors:  J A McSherry
Journal:  Can Med Assoc J       Date:  1983-03-15       Impact factor: 8.262

Review 10.  The initiation and prevention of multiple sclerosis.

Authors:  Alberto Ascherio; Kassandra L Munger; Jan D Lünemann
Journal:  Nat Rev Neurol       Date:  2012-10-09       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.